This inventor holds 1 USPTO granted patent. Top assignees: Jiangsu Hengrui Medicine Company Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Shude Yan: Innovator in Anti-CD40 Antibody Development
Introduction
Shude Yan is a notable inventor based in Lianyungang, China. He has made significant contributions to the field of medical science, particularly in the development of antibodies for therapeutic use. His work focuses on innovative solutions for treating diseases mediated by CD40.
Latest Patents
Shude Yan holds a patent for an "Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof." This patent provides a comprehensive approach to utilizing an anti-CD40 antibody and its fragments for medical applications. The invention includes a chimeric antibody and a humanized antibody that incorporates a CDR region of the anti-CD40 antibody. Additionally, it outlines a pharmaceutical composition that includes the human anti-CD40 antibody and its antigen binding fragment, specifically aimed at treating CD40-mediated diseases or disorders, including applications as an anti-cancer drug.
Career Highlights
Throughout his career, Shude Yan has worked with prominent companies in the pharmaceutical industry. He has been associated with Jiangsu Hengrui Medicine Company Ltd. and Shanghai Hengrui Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in antibody development and medical applications.
Collaborations
Shude Yan has collaborated with several professionals in his field, including Jiahua Jiang and Qiyue Hu. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in medical science.
Conclusion
Shude Yan's contributions to the development of anti-CD40 antibodies represent a significant advancement in medical therapeutics. His innovative work continues to pave the way for new treatments for CD40-mediated diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile